Ingenol mebutate was approved by the FDA in January 2012, and it is marketed under the name Picato®. Picato gel is indicated for the topical treatment of actinic keratosis. Before approval, ingenol mebutate was called PEP005 as an investigational drug. PEP005 is a selective small molecule activator of protein kinase C (PKC) extracted from the plant Euphorbia peplus, whose sap has been used as a traditional medicine for the treatment of skin conditions including warts and cancer. PEP005 also has potent anti-leukemic effects, inducing apoptosis in myeloid leukemia cell lines and primary AML cells at nanomolar concentrations.
For the topical treatment of actinic keratosis.
Long Island Skin Cancer and Dermatologic Surgery, Smithtown, New York, United States
Charité - Universitätsmedizin Berlin, Berlin, Germany
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.